An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non–small-cell ...
177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A ...
University of Navarra (Spain) researchers have developed RNACOREX, a new open-source software capable of identifying gene ...
We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor–positive metastatic breast cancer who had been ...
p.270 The RECID Data Set: Arrest Times for Released Prisoners p.271 The STAN Data Set: Stanford Heart Transplant Patients p.272 The BREAST Data Set: Survival Data for Breast Cancer Patients p.272 The ...
Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge ...
The typical goal in survival analysis is to characterize the distribution of the survival time for a given population, to compare this survival time among different groups, or to study the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback